S Faraz Chavoushi1, Bindia Jharap2, Philip Friedrich2, Kees Smid3, Godefridus J Peters3, Mirte Malingré4. 1. Department of Clinical Pharmacy, Meander Medical Center, Amersfoort, The Netherlands. faraz.chavoushi@gmail.com. 2. Department of Gastroenterology and Hepatology, Meander Medical Center, Amersfoort, The Netherlands. 3. Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands. 4. Department of Clinical Pharmacy, Meander Medical Center, Amersfoort, The Netherlands.
Abstract
PURPOSE: Many patients with Crohn's disease (CD) and ulcerative colitis (UC) who have a high6-methylmercaptopurine/6-thioguanine (6-MMP/6-TGN) ratio receive allopurinol 100 mg in addition to thiopurines to optimize metabolite concentrations. However, some patients do not tolerate allopurinol at this dosage. The aim of this study was to determine the intra-patient effect of reducing the allopurinol dosage from 100 to 50 mg, in terms of metabolite concentrations, enzyme activities, efficacy, and tolerability. METHODS: A prospective non-inferiority one-way crossover study was performed. CD and UC patients with stable disease using athiopurine and allopurinol 100 mg were switched to 50 mg for 1 month. Primary outcomes were thiopurine metabolite concentrations. Secondary outcomes were enzyme activities of xanthine oxidase, thiopurine methyltransferase and hypoxanthine-guanine phosphoribosyltransferase, disease activity, and tolerability. RESULTS:Twenty-two patients were included. Treatment with allopurinol 50 mg compared with 100 mg resulted in a significant decrease in mean 6-TGN levels (761 to 625 pmol/8 × 108 RBC; p = 0.005) and a significant increase in mean 6-MMP levels (451 to 665 pmol/8 × 108 RBC; p = 0.01). However, the mean metabolite concentrations were still therapeutic. Enzyme activities, disease activity scores, and patient experiences did not alter significantly. Generally, UC patients were more positive about their improved treatment than CD patients. CONCLUSION: Combination therapy with 50 mg allopurinol led to a decrease of 6-TGN levels compared with 100 mg allopurinol. Disease activity, side effects, and patient experience, however, were similar between allopurinol 100 and 50 mg. UC patients seem to benefit and prefer lower doses whereas the contrary is seen in CD patients. TRIAL REGISTRATION: EudraCT trial registry - number 2016-001638-84.
RCT Entities:
PURPOSE: Many patients with Crohn's disease (CD) and ulcerative colitis (UC) who have a high 6-methylmercaptopurine/6-thioguanine (6-MMP/6-TGN) ratio receive allopurinol 100 mg in addition to thiopurines to optimize metabolite concentrations. However, some patients do not tolerate allopurinol at this dosage. The aim of this study was to determine the intra-patient effect of reducing the allopurinol dosage from 100 to 50 mg, in terms of metabolite concentrations, enzyme activities, efficacy, and tolerability. METHODS: A prospective non-inferiority one-way crossover study was performed. CD and UCpatients with stable disease using a thiopurine and allopurinol 100 mg were switched to 50 mg for 1 month. Primary outcomes were thiopurine metabolite concentrations. Secondary outcomes were enzyme activities of xanthine oxidase, thiopurine methyltransferase and hypoxanthine-guanine phosphoribosyltransferase, disease activity, and tolerability. RESULTS: Twenty-two patients were included. Treatment with allopurinol 50 mg compared with 100 mg resulted in a significant decrease in mean 6-TGN levels (761 to 625 pmol/8 × 108 RBC; p = 0.005) and a significant increase in mean 6-MMP levels (451 to 665 pmol/8 × 108 RBC; p = 0.01). However, the mean metabolite concentrations were still therapeutic. Enzyme activities, disease activity scores, and patient experiences did not alter significantly. Generally, UCpatients were more positive about their improved treatment than CDpatients. CONCLUSION: Combination therapy with 50 mg allopurinol led to a decrease of 6-TGN levels compared with 100 mg allopurinol. Disease activity, side effects, and patient experience, however, were similar between allopurinol 100 and 50 mg. UCpatients seem to benefit and prefer lower doses whereas the contrary is seen in CDpatients. TRIAL REGISTRATION: EudraCT trial registry - number 2016-001638-84.
Authors: Melissa A Smith; Paul Blaker; Anthony M Marinaki; Simon H Anderson; Peter M Irving; Jeremy D Sanderson Journal: J Crohns Colitis Date: 2012-03-03 Impact factor: 9.071
Authors: Frank Hoentjen; Margien L Seinen; Stephen B Hanauer; Nanne K H de Boer; David T Rubin; Gerd Bouma; Laura E Harrell; Adriaan A van Bodegraven Journal: Inflamm Bowel Dis Date: 2013-02 Impact factor: 5.325
Authors: Sharon J Gardiner; Richard B Gearry; Michael J Burt; Teresa Chalmers-Watson; Bruce A Chapman; Alison G Ross; Catherine A M Stedman; Alexander Huelsen; Murray L Barclay Journal: J Gastroenterol Hepatol Date: 2011-01 Impact factor: 4.029
Authors: M P Sparrow; S A Hande; S Friedman; W C Lim; S I Reddy; D Cao; S B Hanauer Journal: Aliment Pharmacol Ther Date: 2005-09-01 Impact factor: 8.171
Authors: B Jharap; M L Seinen; N K H de Boer; J R van Ginkel; R K Linskens; J C Kneppelhout; C J J Mulder; A A van Bodegraven Journal: Inflamm Bowel Dis Date: 2010-09 Impact factor: 5.325
Authors: Fernando Gomollón; Axel Dignass; Vito Annese; Herbert Tilg; Gert Van Assche; James O Lindsay; Laurent Peyrin-Biroulet; Garret J Cullen; Marco Daperno; Torsten Kucharzik; Florian Rieder; Sven Almer; Alessandro Armuzzi; Marcus Harbord; Jost Langhorst; Miquel Sans; Yehuda Chowers; Gionata Fiorino; Pascal Juillerat; Gerassimos J Mantzaris; Fernando Rizzello; Stephan Vavricka; Paolo Gionchetti Journal: J Crohns Colitis Date: 2016-09-22 Impact factor: 9.071